Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper (Q46522736)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2013

Language	Label	Description	Also known as
English	Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper	scientific article published in May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

1 reference

based on heuristic

inferred from title

author name string

Boris Gorovits

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Stephen C Alley

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Sanela Bilic

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Brian Booth

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Surinder Kaur

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Phillip Oldfield

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Shobha Purushothama

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Chetana Rao

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Stacy Shord

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Patricia Siguenza

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

publication date

1 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

997-1006

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Antibody conjugate therapeutics: challenges and potential

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Renaissance of cancer therapeutic antibodies

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Therapeutic antibodies: successes, limitations and hopes for the future

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Arming antibodies: prospects and challenges for immunoconjugates

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Pharmacokinetic considerations for antibody drug conjugates

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Tunable degradation of maleimide-thiol adducts in reducing environments

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Contribution of linker stability to the activities of anticancer immunoconjugates

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Drug metabolites in safety testing

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.38

21 January 2018

Identifiers

10.4155/BIO.13.38

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23641692

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46522736&oldid=2115836086"